Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 11/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14906850 | 1.00 | TAAR1 (0.57) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL18723730 | 1.00 | TAAR1 (0.57) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL2085299 | 0.80 | — | — | |
| SCHEMBL28945858 | 0.77 | TAAR1 (0.57) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL28515743 | 0.77 | TAAR1 (0.60) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL28511084 | 0.77 | TAAR1 (0.60) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL21282227 | 0.77 | TAAR1 (0.71) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL28515741 | 0.77 | TAAR1 (0.60) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL30733601 | 0.77 | TAAR1 (0.60) | TAAR1HTR1ADRD2HTR7KEAP1 | |
| SCHEMBL28511085 | 0.77 | TAAR1 (0.60) | TAAR1HTR1ADRD2HTR7KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | TAAR1 2272/4885HTR1A 394/4885DRD2 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.